Hygeia Completes $1M Series A

Xconomy Boston — 

Hygeia Therapeutics, a Holden, MA, developer of hormone-based topical drugs, has closed a $1 million round of Series A funding, the company announced today. Hygeia did not reveal the investors in the round, but said the funding will go to testing its topical synthetic estrogen drug designed to treat age-related skin thinning, and will fuel the development of a topical anti-androgen drug.

By posting a comment, you agree to our terms and conditions.

Comments are closed.